SecBot SecBot
8-K ·Filed Jun 9, 2026

ESPR

Esperion Therapeutics, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed5mo ago SEC0001104659-26-071814
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The German clearance removes a material condition precedent, increasing the probability of deal completion. Monitor the July 8 stockholder vote and any HSR developments. The stock should trade closer to the implied deal price as remaining conditions are resolved.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$3.14
T+0 close · Jun 9, 2026 · via day close
Latest settled
+1.59%
T+20 · $3.19
Vs SPY
−2.03%
α at T+20
Next horizon
T+60
due 2mo ago
  1. T+0 · Jun 10 $3.14entry
  2. T+1 · 5mo ago +0.32%α −1.38% · $3.15
  3. T+5 · 5mo ago +0.64%α −2.80% · $3.16
  4. T+20 · 4mo ago +1.59%α −2.03% · $3.19
  5. T+60 · due 2mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Esperion Therapeutics disclosed that the German Federal Cartel Office (Bundeskartellamt) cleared the pending acquisition by an affiliate of ArchiMed SAS, effective June 2, 2026. The merger remains subject to other conditions, including HSR clearance and stockholder approval at a special meeting scheduled for July 8, 2026.

Key Facts

  • Bundeskartellamt cleared the merger effective June 2, 2026.
  • Special stockholder meeting to vote on the merger is set for July 8, 2026.
  • Completion still requires HSR waiting period expiration/termination and stockholder adoption of the merger agreement.

Financial Impact

Removal of a key regulatory hurdle in Germany; deal value not disclosed in this filing.

Risk Factors

  • Stockholder vote may not pass.
  • HSR waiting period could be extended or challenged.
  • Other closing conditions may not be satisfied.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-071814
Document: 0001104659-26-071814-index-headers.html0001104659-26-071814
Document: 0001104659-26-071814-index.html0001104659-26-071814
Document: 0001104659-26-071814.txt0001104659-26-071814

Track record

21 reports on ESPR

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
  2. Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
  3. Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
  4. Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
  5. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  6. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  7. Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
  8. Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
  9. Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
  10. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 9, 2026